The European Commission has authorised the use of Sanofi and Lexicon’s Zynquista (sotagliflozin) in Europe in the treatment of specific patients with type 1 diabetes (T1D), it has been revealed.
The oral SGLT1 and 2 inhibitor was approved in both 200 mg and 400 mg doses as an adjunct to insulin therapy to improve glycaemic control in adults with type 1 diabetes mellitus and a body mass index ? 27 kg/m2, who could not achieve adequate control despite optimal insulin therapy.
